Experience with long-term use of certolizumab pegol (Cimzia)

Experience with long-term use of certolizumab pegol (Cimzia)

Show other versions (1)

Bibliographic Details
Main Authors:	Karine Arnoldovna Lytkina, G P Arutyunov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2013-10-01
Series:	Современная ревматология
Subjects:	ревматоидный артрит генно-инженерные биологические препараты базисные препараты цертолизумаба пэгол
Online Access:	https://mrj.ima-press.net/mrj/article/view/496

Similar Items

The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

A healthy and nuclear family of a patient with inflammatory disease: topical issues and ways of their solution. What can modern medicine offer?
by: A. M. Lila
Published: (2018-04-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01)

Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups
by: Yu. Yu. Grabovetskaya
Published: (2020-09-01)

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

Comorbid infections in patients with rheumatoid arthritis
by: B.S. Belov
Published: (2014-05-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)

Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01)

TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY
by: D. I. Khusainova, et al.
Published: (2020-06-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

Efficacy and tolerability of adalimumab (humira) in patients with active rheumatoid arthritis
by: I G Salikhov, et al.
Published: (2010-12-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Current issues in the management of patients with HIV infection and rheumatic diseases
by: G. I. Gridneva, et al.
Published: (2021-12-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

EFFICACY OF ABATACEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO TNF-α
by: Yu. M. Spivakovskii, et al.
Published: (2015-04-01)

Perioperative Management of Patients with Rheumatic Diseases: Glucocorticoids, DMARDs, Biological Agents and NSAIDs
by: V. V. Lyalina, et al.
Published: (2022-02-01)

RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS
by: G. V. Santalova, et al.
Published: (2019-03-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis
by: M. A. Kotovskaya, et al.
Published: (2017-04-01)

Evaluation of the efficacy of standard basic anti-inflammatory drugs and the time to start basictherapy for rheumatoid arthritis
by: Irina Mikhailovna Marusenko
Published: (2010-12-01)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol’skaja, et al.
Published: (2015-11-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Comorbid infections in spondyloarthritis: a modern view of the problem
by: N. V. Muravyeva, et al.
Published: (2020-11-01)

MANAGEMENT PROTOCOL FOR PATIENTS WITH JUVENILE ARTHRITIS
by: A. A. Baranov, et al.
Published: (2013-02-01)

EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01)